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Abstract Aminoacyl tRNA synthetases are enzymes in-
volved in the key process of coupling an amino acid to its
cognate tRNA. AN3365 is a novel antibiotic that specifically
targets leucyl-tRNA synthetase, whose development was
halted after evaluation in phase II clinical trials owing to the
rapid selection of resistance. In an attempt to bring AN3365
back into the developmental pipeline we have evaluated the
efficacy of AN3365 in combination with different classes of
antibiotic and characterized its mechanism of action.
Although we detect no synergy or antagonism in combination
with a range of antibiotic classes, a combination of AN3365
with colistin reduces the accumulation of AN3365-resistant
and colistin resistance mutations. We also demonstrate that
treatment with AN3365 results in the dramatic accumulation
of the alarmone (p)ppGpp, the effector of the stringent re-
sponse—a key player in antibiotic tolerance.
Introduction
Aminoacyl-tRNA synthetases (aaRS) catalyze an essential
step in protein synthesis—the attachment of amino acids to
the corresponding tRNAs [1, 2]. They are a promising target
for the development of new antibiotic compounds because of
their universal nature and the significant structural and bio-
chemical differences between bacterial and eukaryotic aaRS
[3, 4]. In this respect, the broad-spectrum antibacterial agent
AN3365 was recently developed to selectively target the
leucyl-tRNA synthetase (LeuRS) of Gram-negative bacteria
[5]. Although the compound has good activity toward drug-
resistant Gram-negative organisms, its development was
halted during phase II clinical trials owing to the rapid selec-
tion of resistant mutants in 3 out of 14 patients enrolled in the
study [6].
However, the development of new antibiotics is a slow and
costly process and it is therefore crucial that promising lead
compounds are extensively tested before they are discarded.
Therefore, a further detailed characterization of AN3365 was
performed to help guide the further development of more clin-
ically suitable aminoacyl-tRNA synthetase inhibitors for
Gram-negative bacteria [7, 8]. The authors evaluated the an-
tibacterial properties of AN3365 using a range of clinically
relevant, multi-resistant and susceptible Gram-negative and
Gram-positive bacteria: the so-called ESKAPE bacteria, i.e.,
Enterococcus faecium (E. faecium), Staphylococcus aureus
(S. aureus), Klebsiella pneumoniae (K. pneumoniae),
Acinetobacter baumannii (A. baumannii), Pseudomonas
aeruginosa (P. aeruginosa), Enterobacter spp., and
Escherichia coli (E. coli). We evaluated the possible
synergistic/antagonistic effects of AN3365 in combination
with different classes of antibiotics in vitro, and determined
the mutation frequencies for the bacterial species E. coli,
K. pneumoniae, and P. aeruginosa. Finally, we showed that
AN3365 efficiently triggers the so-called bacterial Bstringent
response^ (a stress response activated in bacteria by, for ex-
ample, amino-acid starvation). Activation of the stringent re-
sponse is orchestrated by rapid accumulation of the alarmone
nucleotide (p)ppGpp, which leads to a reduction in bacterial
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growth and replication, with an emphasis on the production of
proteins involved in amino-acid synthesis instead (https://en.
wikipedia.org/wiki/Stringent_response).
Materials and methods
Bacterial isolates
To determine the efficacy of AN3365, the in vitro antibacterial
activity of AN3365 was tested against a panel of 1,252 bacterial
isolates (734 multi-resistant + 518 blood culture isolates)
consisting of 889 Gram-negative and 363 Gram-positive bacte-
ria. Most of the strains were obtained from the biobanked strain
collection of the Erasmus Medical Center Rotterdam (the
Netherlands) with others originating from Iraq, Indonesia,
Paraguay, Bangladesh, Saudi Arabia, and Brazil. The
multidrug-resistant bacteria included isolates carrying plasmid-
encoded pAmpC β-lactamases, extended spectrum beta-
lactamases (ESBL), carbapenemase positive (KPC+),
oxacillinases-48-like (OXA-48), New Delhi metallo-beta-
lactamase (NDM), IMP-type carbapenemases (IMP), Verona
integron-encoded metallo-β-lactamase (VIM), methicillin-
resistant Staphylococcus aureus (MRSA), and vancomycin-
resistant enterococci (VanA, VanB). These strains had previously
been identified in our laboratory using MALDI-TOF mass spec-
trometry (Biotyper; Bruker Daltonics, Bremen, Germany), and
the presence of the corresponding resistance genes was verified
by PCR.
Susceptibility determination
Minimal inhibitory concentration (MIC) values for dif-
ferent antibiot ics were determined using broth
microdilution performed in accordance with EUCAST
guidelines. Briefly, a standard inoculum of 0.5
McFarland units (approximately 5 × 107 CFU/ml) was
prepared in sa l ine for each bac te r ia l i so la te .
Subsequently, the inoculum was diluted 100 times in
Mueller–Hinton II (MH II; Becton, Dickinson and
Company) broth to obtain a concentration of approxi-
mately 5 × 105 CFU/ml. One hundred microliters of this
bacterial suspension was then added to 100 μl of two-
fold serial dilutions of the test antibiotic, which had
been previously prepared in MH II broth. After incuba-
tion at 37 °C, growth or no growth of the bacteria was
determined by visually checking the turbidity of the
different antibiotic dilutions.
Synergy testing
In addition to susceptibility testing, we investigated if AN3365
possessed any synergistic properties when used in combination
with different classes of clinically relevant antibiotics. Synergy
studies were aimed at demonstrating a reduction in the MICs for
the combination of antibiotics compared with individual antibi-
otics used alone. Twenty strains of blood culture isolates of
E. coli and K. pneumoniae were tested for growth in vitro in
the presence of combinations of AN3365 with gentamicin (ami-
noglycoside), cefuroxime (second-generation cephalosporin),
ceftazidime (third-generation cephalosporin), meropenem (car-
bapenem antibiotic), and ciprofloxacin (fluoroquinolone).
Synergy testing was performed using the checkerboard method-
ology as follows: a standard inoculum equal to 0.5 McFarland
units was prepared for each bacterial isolate in saline. One hun-
dred microliters of this bacterial suspension was then added to
100 μl of two-fold serial dilutions of the test antibiotics (previ-
ously prepared in MH II broth) using a checkerboard pattern—
the first antibiotic of the combination was serially diluted along
the x-axis, whereas the second antibiotic was diluted along the y-
axis. Synergistic or antagonistic activity was determined using
the sum of the fractional inhibitory concentration index (ΣFIC).
TheΣFIC is calculated as the sum of FICA + FIC B, where FIC
A is the MIC of drug A in the combination of drugs A and B
divided by the MIC of drug A alone, plus the MIC of drug B in
the combination of drugs A and B divided by theMIC of drug B
alone. A combination of drugs is considered synergistic when the
ΣFIC is ≤0.5, indifferent when the ΣFIC is >0.5 to <2, and
antagonistic when the ΣFIC is ≥2 [9].
Determination of mutation frequencies
Mutants were obtained by plating dilutions of overnight cultures
grown inMH II broth on agar plates containing no antibiotic, and
4-fold or 10-fold MIC concentrations of AN3365, the compara-
tor drug, or combinations of AN3365 and the comparator drug
(ceftazidime and colistin). Colonies were counted after 48 h of
incubation at 37 °C. The mutation frequency was determined by
dividing the number of CFU/ml determined either at 4-fold or
10-fold MIC of AN3365 by the CFU/ml obtained without anti-
biotic exposure.
Determination of time-to-mutation
Colonies of K. pneumoniae ATCC27853 and K. pneumoniae
EMC-KPC (a KPC carrying strain of K. pneumoniae) were
grown to a concentration of 5 × 105 CFU/ml in 96-well plates
of: medium consisting of MH II broth; MH II broth containing a
sub-inhibitory concentration of AN3365 (0.2 μg/ml); MH II
broth containing a sub-inhibitory concentration of colistin
(0.06 μg/ml), and MH II broth containing mixed sub-inhibitory
concentrations of AN3365 and colistin (0.2 and 0.06 μg/ml). At
time points 0, 1, 2, 3, 4, 5, 6, and 24 h, 5 μl of bacterial cultures
were transferred to new 96-well plates containing either MH II
broth, MH II broth containing 4 times the MIC of AN3365, MH
II broth containing 4 times the MIC of colistin, or MH II broth
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containing 4 times the MIC of both AN3365 and colistin. After
overnight incubation at 37 °C, growth/no growthwas determined
by visually checking the turbidity of the different combinations.
Determination of (p)ppGpp levels
To determine the accumulation of (p)ppGpp in response to treat-
ment with AN3365,E. coli strainMG1655was grown overnight
at 37 °C in morpholinepropanesulfonic acid (MOPS) medium
(Teknova) with shaking at 220 rpm. The next day, cells were
diluted 100 times in 400 ml MOPS medium and grown at
37 °C until an OD600 of 0.4 was achieved. The culture was then
split into equal volumes of 200 ml in two flasks, and AN3365
was added to one of these flasks at a concentration 5 times the
MIC. After that, cultures were returned to the incubator. Samples
for nucleotide measurements were then collected at 15, 30, and
60 min after the addition of AN3365. Nucleotides were then
extracted following a protocol adapted from the procedure de-
scribed by Buckstein and colleagues [10], except that nucleotides
were eluted from the HiTrap Q Sepharose FF (GE Healthcare
Life Sciences) column using 2M LiCl in 25 mM Tris pH 8 with
a flow rate of 1 ml/min. Elution was followed at 254 nm.
Subsequently, 4 volumes of 96 % ethanol (−20 °C) and 4 μl of
ice-cold 1 M K2HPO4 were added to the collected fractions to
promote the formation of a nucleotide precipitate and left to
precipitate over night at −20 °C. The next day, the sample was
centrifuged for 20 min at 5525 G at 4 °C using a swing-out rotor
(centrifuge Sigma 4K15C) to collect the precipitate. The super-
natant was discarded and the resulting precipitate was washed
with 5 ml of 70 % cold ethanol and centrifuged for another
20 min at 5,525 G at 4 °C. After this time, the supernatant was
again discarded and the resulting sample was lyophilized and
then dissolved in 300 μl of cold mQ with heavy vortexing.
Nucleotides were then analyzed by anion exchange high-
pressure liquid chromatography (HPLC) using anAgilent system
with UV detection at 254 nm and peak height was used for
estimating nucleotide amounts. For HPLC, a Waters Spherisorb
S5 SAX (4.6 × 250 mm) column equipped with a Spherisorb
SAX guard column was used. A flow rate of 1.0 ml/min, and a
linear gradient of 100:0 to 0:100 (Buffer A:Buffer B) was used,
with a run time of 30 min. Buffer A comprised 0.05 M ammo-
nium phosphate (pH 3.4), and buffer B 0.5 M ammonium phos-
phate (pH 3.4). Nucleotide standards were obtained from Sigma,
and the ppGpp standard was obtained from TriLink
BioTechnologies (San Diego, CA, USA).
Results
MIC distribution
Determination of MICs using AN3365 and a panel of
1,252 bacterial strains consisting of 889 Gram-negative
and 363 Gram-positive bacteria showed that the vast
majority of isolates were susceptible to AN3365 at
MICs ranging from 0.25 to 2 μg/ml. As previously
reported, AN3365 proved to be a very effective drug
against Enterobacteriaceae [5], with most of the blood
isolates being inhibited at 0.5 μg/ml (52 % of all Gram-
negative isolates; Table 1) and the multi-resistant isolates
Table 1 Minimum inhibitory concentrations (MIC) and cumulative MIC distribution for AN3365 using clinical blood culture isolates of
Enterobacteriaceae, non-fermentative Gram-negative and Gram-positive bacteria
Isolates Number of strains (cumulative %) inhibited at MIC (μg/ml) of Number of isolates tested MIC
0.25 0.5 1 2 4 8 16 32 ≥64 50 % 90 %
A. baumannii 4 (19) 2 (28) 9 (71) 5 (95) 1 (100) 21 1 2
C. freundii 8 (80) 2 (100) 10 0.5 1
C. koseri 4 (25) 12 (100) 16 0.5 0.5
E. cloacae 1 (2) 39 (82) 7 (96) 2 (100) 49 0.5 1
E. coli 33 (65) 18 (100) 51 0.5 1
E. faecalis 1 (2) 13 (29) 24 (77) 11 (100) 49 8 16
E. faecium 49 (100) 49 128 128
K. pneumoniae 34 (69) 11 (92) 4 (100) 49 0.5 1
M. morganii 14 (53) 6 (83) 4 (100) 24 0.25 1
P. aeruginosa 3 (6) 23 (56) 13 (58) 7 (100) 46 2 8
P. mirabilis 14 (29) 32 (95) 2 (100) 48 1 1
P. vulgaris 2 (40) 3 (100) 5 1 1
S. aureus 48 (92) 3 (98) 1 (100) 52 4 4
S. marcescens 4 (8) 40 (80) 6 (100) 50 0.5 1
Bacteria used were clinical isolates originating from the Netherlands, isolated between 2010 and 2014
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at 1 μg/ml (62 % of all Gram-negative isolates, Table 2).
All the Gram-negative strains tested were inhibited at a
concentration of 2 μg/ml (Tables 1, 2). For the non-
fermenting bacteria, most P. aeruginosa isolates were
inhibited at 2 μg/ml (69 % of multi-resistant isolates and
56 % of blood culture), whereas A. baumannii isolates
were mainly inhibited at 1 μg/ml (38 % of multi-
resistant isolates and 43 % of blood isolates; Tables 1,
2). In the case of Gram-positive bacteria, E. faecium iso-
lates showed MICs ≥128 μg/ml, whereas the growth of
MRSA (methicillin-resistant S. aureus) and blood isolates
of S. aureus was inhibited at 4 μg/ml (81 % of MRSA and
92 % of blood isolates). E. faecalis isolates were mostly
inhibited at 8 μg/ml (60 % of all E. faecalis strains). All
Gram-positives tested, with the exception of E. faecium
isolates, were inhibited at a concentration of AN3365 of
16 μg/ml (Tables 1, 2).
Synergy studies
No synergistic effect was observed for any of the combina-
tions of AN3365 with different antibiotic classes (Table 3). In
combination with other antibiotics, AN3365 mainly showed
an indifferent profile, with an FIC 50 % of 1.5 for
K. pneumoniae and between 1.5 and 2 for E. coli and
P. aeruginosa (Table 3). AN3365 in combination with genta-
micin or cefuroxime showed an antagonistic effect for 2 out of
the 20 isolates of K. pneumoniae tested (data not shown).
Mutation frequencies for AN3365 and colistin
It has been shown thatE. coli, P. aeruginosa, andK. pneumoniae
possess in vitro mutation frequencies of 1 × 10−7 to 8 × 10−7 for
AN3365 [5]. This mutation rate is high compared with non-
antibiotic exposed bacteria, but comparable with that observed
when bacteria are exposed to other antibiotics such as ciproflox-
acin or ceftazidime [5]. In our experiments, we observed a similar
rate of mutation frequencies for at least two strains of E. coli,
P. aeruginosa, and K. pneumoniae with mutants appearing with
frequencies between 0.76 × 10−8 and 2.6 × 10−7 (Table 4). When
using a combination of AN3365 and colistin, the mutation fre-
quency was much reduced (within the limit of detection of the
test protocol), with no mutants appearing when a combination of
the two drugs at 4 times their MIC was used (data not shown).
The time taken for resistance mutations to appear when
incubated without antibiotic exposure and with sub-
inhibitory antibiotic exposure are shown in Table 5.
Turbidity, corresponding to the presence of antibiotic resis-
tance mutants, could only be observed in 96-well plates con-
taining single antibiotics, with growth appearing 5–24 h after
exposure to the antibiotic (Table 5). When a combination of
two antibiotics was used no turbidity was observed. This find-
ing is in agreement with results obtained using solid MH II
agar media plates, where mutants for AN3365 and colistin
were selected after a single exposure to the individual antibi-
otic (Table 6). Further, plates containing a combination of
AN3365 and colistin showed a marked reduction in mutation
frequency even when isolates were grown in medium contain-
ing sub-inhibitory concentrations of the two antibiotics for
24 h (Table 6).
Accumulation of (p)ppGpp
AN3365 specifically inhibits E. coli LeuRS [5], leading to the
accumulation of uncharged tRNA (leading to the induction of the
alarmone (p)ppGpp by the stringent response factor RelA [10,
11]). The addition of 5 μg/ml (5xMIC) of AN3365 induced
dramatic accumulation of ppGpp, with the ratio of ppGpp to
GTP changing from 0.021 ± 0.002 (untreated culture) to 1.51 ±
0.01 after 15 min of AN3365 treatment (Fig. 1.).
Table 2 The MICs and cumulative MIC distribution for AN3365 in a range of multi-resistant isolates of Enterobacteriaceae, non-fermentative Gram-
negative and Gram-positive bacteria
Isolates Number of strains (cumulative %) inhibited at MIC (μg/ml) of Number of isolates tested MIC
0.25 0.5 1 2 4 8 16 32 ≥64 50 % 90 %
A. baumannii 3 (3) 41 (41) 31 (70) 25 (93) 7 (100) 107 2 4
E. cloacae 14 (15) 60 (68) 31 (97) 3 (100) 108 0.5 1
E. coli 23 (22) 69 (89) 11 (100) 103 1 2
K. pneumoniae 30 (27) 68 (82) 14 (100) 112 1 2
S. aureus 88 (81) 19 (98) 2 (100) 109 4 8
Enterococci 105 (100) 105 128 128
P. aeruginosa 18 (2) 44 (69) 17 (88) 6 (94) 5 (100) 90 2 8
Bacteria used were clinical isolates originating from the Netherlands, Iraq, Indonesia, Paraguay, Bangladesh, Saudi Arabia, and Brazil, isolated between
2010 and 2014
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Table 4 Mutation frequencies
for AN3365 and ceftazidime Microorganism Antibiotic MIC (μg/
ml)
Concentration MIC
multiple
Mutation
frequency
E. coli ATCC 25922 AN3365 0.5 4-fold 1.15 × 10−7
10-fold 2 × 10−8
E. coliMG1655 AN3365 0.5 4-fold 1.5 × 10−7
10-fold 0.76 × 10−8
K. pneumoniae ATCC
13883
AN3365 1 4-fold 1.4 × 10−7
10-fold 6.6 × 10−8
K. pneumoniae C10 AN3365 1 4-fold 1.1 × 10−7
10-fold 0.9 × 10−7
P. aeruginosaATCC 27853 AN3365 4 4-fold 1.2 × 10−7
10-fold 8.5 × 10−8
P. aeruginosa JR 326 AN3365 2 4-fold 2.6 × 10−7
10-fold 4.4 × 10−8
E. coli ATCC 25922 Ceftazidime 0.25 4-fold ND
10-fold ND
E. coliMG1655 Ceftazidime 0.5 4-fold ND
10-fold ND
K. pneumoniae ATCC
13883
Ceftazidime 0.25 4-fold ND
10-fold ND
K. pneumoniae C10 Ceftazidime >64 4-fold ND
10-fold ND
P. aeruginosaATCC 27853 Ceftazidime 2 4-fold 2.2 × 10−8
10-fold 1.1 × 10−8
P. aeruginosa JR 326 Ceftazidime >64 4-fold ND
10-fold ND
Mutation frequencies were determined for E. coli ATCC 25922, E. coli MG1655, and K. pneumoniae ATCC
13883 after overnight culture and assessing the growth or no growth of antibiotic-resistant colonies.
K. pneumoniae (KPC+ ) C10 and P. aeruginosa JR 326 were resistant to ceftazidime
Table 3 Fractional inhibitory
concentration (FIC) range and
cumulative FIC for 20 clinical
isolates ofE. coli,K. pneumoniae,
and P. aeruginosa tested for the
combination of AN3365 with
either gentamicin, cefuroxime,
ceftazidime, ciprofloxacin,
meropenem or tobramycin
Bacteria E. coli K. pneumoniae P. aeruginosa
Antibiotics FIC
range
FIC
50 %
95 % FIC
range
FIC
50 %
95 % FIC
range
FIC
50 %
95 %
AN3365 Gentamicin 1.1–
2.0
2.0 2.0 0.9–
2.4
1.5 2.2 ND ND ND
AN3365 Cefuroxime 1.0–
2.5
1.5 2.0 1.0–
3.0
1.5 3.0 ND ND ND
AN3365 Ceftazidime 0.9–
2.0
1.5 2.0 1.4–
2.5
1.5 2.0 0.7–
2.0
1.5 2.0
AN3365 Ciprofloxacin 1.1–
2.2
1.5 2.0 1.0–
2.5
1.5 2.0 1.2–
2.5
2.0 2.0
AN3365 Meropenem 0.7–
2.0
2.0 2.0 0.7–
2.0
1.4 2.0 1.0–
2.5
2.0 2.0
AN3365 Tobramycin ND ND ND ND ND ND 0.7–
2.0
1.5 2.0
The combination of AN3365 together with tobramycin for E. coli and K. pneumoniae was not determined (ND)
because tobramycin is not clinically relevant for the treatment of E. coli or K. pneumoniae infections. The
combinations of AN3365 together with gentamicin or cefuroxime for P. aeruginosawere ND because gentamicin
and cefuroxime are not relevant for the treatment of infections caused by P. aeruginosa
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Discussion
Aminoacyl tRNA synthetases may be an excellent target
for antibiotics. On the one hand, they catalyze the funda-
mental process of linking an amino acid to its correspond-
ing tRNA, an essential and universal step for protein syn-
thesis in all life forms [12]. On the other hand, there are
significant differences in aminoacyl tRNA synthetases be-
tween bacteria and eukaryotes to allow the selective
targeting of these enzymes to pathogenic bacteria without
interfering with host protein synthesis [1, 12].
In this publication, the authors have re-evaluated
AN3365, a novel leucyl-tRNA synthetase inhibitor with
a good spectrum of activity toward Enterobacteriaceae,
but whose development was previously halted in phase
II clinical trials owing to the rapid development of resis-
tance to AN3365 in subjects presenting with complicated
urinary tract infections [6]. Our MIC analyses showed that
AN3365 was able to efficiently inhibit the growth of
multi-resistant, pathogenic, Gram-negative bacteria at
concentrations of approximately 1 μg/ml. Comparable
MICs were also observed against the non-fermenting bac-
teria P. aeruginosa and A. baumannii, and to a lesser
extent, activity was observed against the Gram-positive
pathogens S. aureus and E. faecalis. Interestingly,
E. faecium was not sensitive to the drug at the maximum
concentration tested of 128 μg/ml. This is probably be-
cause of differences in the structure of the leucyl-tRNA
synthetase of this bacterial species that prevent a stable
interaction between the inhibitor antibiotic (AN3365) and
the E. faecium leucyl-tRNA synthetase molecule. To fur-
ther characterize the activity of AN3365, studies were
also performed to discover whether combinations of
AN3365 with other classes of antibiotic resulted in a syn-
ergistic effect on the antibiotic activity of one or both
antibiotics. Unfortunately, however, all of the antibiotic
combinations tested showed no synergistic activity.
Mutation frequency experiments using AN3365 showed
that exposure to AN3365 led to a relatively high mutation
frequency in E. coli and K. pneumoniae compared with pre-
viously published results using the aminoacyl tRNA synthe-
tase inhibitor mupirocin, a tRNA synthetase inhibitor for top-
ical use only, which specifically inhibits the isoleucyl-tRNA
synthetase of Gram-positive bacteria [13]. With regard to
mupirocin, two resistor phenotypes have been reported: low-
level and high-level resistance [14]. Low-level resistance has
been linked to single point mutations in the target gene, and
high-level resistance is caused by the acquisition of an alter-
native biosynthetic pathway via a mobile genetic element.
Interestingly, the use of a combination of antibiotics, one
bacteriostatic and one bactericidal, i.e., AN3365 and colistin,
resulted in a reduction in the mutation frequencies for clini-
cally relevant isolates of K. pneumoniae. This finding isTa
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probably a result of the inability of bacteria to simultaneously
generate multiple viable mutations when exposed to a combi-
nation of antibiotics that target two different biological
processes within the cell. Perhaps, therefore, it is possible that
the use of AN3365 and colistin together (two antibiotics
where bacteria can relatively quickly generate resistance to
each individual antibiotic via mutation) could enhance the
usefulness of these antibiotics in the clinical situation, espe-
cially as colistin remains the only current treatment option
available for treating extremely resistant Gram-negative
infections.
In bacteria, amino acid starvation triggers the accumulation
of alarmone nucleotides (p)ppGpp, which in turn, orchestrates
the activation of the so-called Bstringent response,^ a global
rewiring of transcription, translation, and metabolism [15].
The stringent response plays an important role in the regula-
tion of bacterial virulence [16] in addition to antibiotic resis-
tance [17] and persistence [18]. Our results indicate that
AN3365 strongly induces the stringent response through accu-
mulation of the alarmone (p)ppGpp, which, in turn, generates a
change in bacterial metabolism via the down-regulation of the
production of ribosomes and the upregulation of, for example,
Table 6 Mutation frequencies
for AN3365 and colistin Microorganism Antibiotic MIC (mg/
ml)
Concentration MIC
multiple
Mutation
frequency
K. pneumoniae ATCC
13883
AN3365 1 4-fold 1.4 × 10−7
10-fold 6.6 × 10−8
K. pneumoniae ATCC
13883*
AN3365* 1 4-fold 8.6 × 10−4
10-fold 6.8 × 10−4
K. pneumoniae ATCC
13883
Colistin 2 4-fold 3.6 × 10−8
10-fold 4 × 10−9
K. pneumoniae ATCC
13883*
Colistin* 2 4-fold 2.3 × 10−6
10-fold 6.2 × 10−6
K. pneumoniae ATCC
13883
AN3365 +
colistin
1 + 2 4-fold Not detected
10-fold Not detected
K. pneumoniae ATCC
13883*
AN3365 +
colistin*
1 + 2 4-fold 6.9 × 10−9
10-fold 6.6 × 10−9
K. pneumoniae EMC-
KPC
AN3365 1 4-fold 1.3 × 10−7
10-fold 6 × 10−8
K. pneumoniae EMC-
KPC*
AN3365* 1 4-fold 6.1 × 10−4
10-fold 5.3 × 10−4
K. pneumoniae EMC-
KPC
Colistin 2 4-fold 0.85 × 10−7
10-fold 0.7 × 10−7
K. pneumoniae EMC-
KPC*
Colistin* 2 4-fold 1.8 × 10−6
10-fold 3.1 × 10−7
K. pneumoniae EMC-
KPC
AN3365 +
colistin
1 + 2 4-fold 7.5 × 10−9
10-fold Not detected
K. pneumoniae EMC-
KPC*
AN3365 +
colistin*
1 + 2 4-fold 1.6 × 10−8
10-fold 4.9 × 10−8
K. pneumoniae ATCC 13883 and K. pneumoniae EMC-KPC were grown overnight in MH II medium without
antibiotics (no asterisk), or with sub-inhibitory concentrations of AN3365 (0.2 mg/ml), colistin (0.06 mg/ml), and
AN3365 mixed with colistin (0.2 mg/ml and 0.06 mg/ml; marked with an asterisk). The next day, cells were
plated on MH II agar plates containing 4-fold or 10-fold MIC concentrations of AN3365, colistin, or a combi-
nation of AN3365 and colistin
Fig. 1 AN3365 induces the accumulation of ppGpp in E. coliMG1655.
a Calibration curve of high-performance liquid chromatography (HPLC)
detection of (p)ppGpp shows a linear response of the signal (in mAU) as a
function of the amount of injected nucleotide (in picomoles). b Liquid
culture of E. coli MG1655 (MOPS medium supplemented with 0.2 %
glucose, OD600 = 0.4, 37 °C, shaking at 220 rpm) was treated with
5 μg/ml AN3365 (5xMIC) for 15 min and nucleotides were measured
using an HPLC-based approach
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amino-acid synthesis genes. When the stringent response is acti-
vated, the bacterial cell enters a Bdormant^ state [19].
In conclusion, even though the antibiotic AN3365 has been
removed from development after disappointing phase II clin-
ical trials, the antibiotic may still have potential clinical value
for use in combinatorial antibiotic therapies targeting
(multiresistant) bacterial infections, as co-administration of
AN3365 with colistin slows down the selection of both
AN3365 and colistin-resistant mutants.
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